Which of the following is the only drug is found to be beneficial in halting the progression on EDSS of multiple sclerosis:
**Core Concept**
Multiple sclerosis (MS) is a chronic autoimmune disease characterized by demyelination, axonal damage, and neurodegeneration in the central nervous system (CNS). The Expanded Disability Status Scale (EDSS) is a widely used measure of disability progression in MS patients. The treatment goals for MS include reducing disease activity, slowing disease progression, and managing symptoms.
**Why the Correct Answer is Right**
Interferon beta-1b (Betaseron) is the only FDA-approved drug that has been shown to slow the progression of disability in patients with relapsing forms of multiple sclerosis, as measured by the EDSS. The mechanism of action of interferon beta-1b involves the induction of anti-inflammatory cytokines, reduction of pro-inflammatory cytokines, and enhancement of the blood-brain barrier integrity. This results in reduced inflammation and damage to the CNS.
**Why Each Wrong Option is Incorrect**
**Option A:** is incorrect because glatiramer acetate (Copaxone) is an immunomodulator that reduces the frequency of relapses in patients with relapsing-remitting MS, but it is not proven to halt the progression of disability as measured by the EDSS.
**Option B:** is incorrect because natalizumab (Tysabri) is a monoclonal antibody that has been shown to reduce the frequency of relapses and slow disease progression in patients with relapsing forms of MS, but it is not FDA-approved for this indication.
**Option C:** is incorrect because fingolimod (Gilenya) is an oral sphingosine 1-phosphate receptor modulator that reduces the frequency of relapses and slows disease progression in patients with relapsing forms of MS, but it is not proven to halt the progression of disability as measured by the EDSS.
**Clinical Pearl / High-Yield Fact**
It's essential to note that the primary goal of MS treatment is to reduce disease activity and slow disease progression, not just to manage symptoms. The choice of therapy should be individualized based on the patient's disease course, severity, and comorbidities.
**Correct Answer:** A.